Myriad Genetics (STU:MYD) Tariff Resilience Score: 7/10 (As of Jul. 12, 2026)


STU:MYD Myriad Genetics Inc STU:MYD
53 GF Score
Price €5.09
GF Value €13.06
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Tariff Resilience Score?

Myriad Genetics STU:MYD -4.18% 53 Tariff Resilience Score is 7 as of Jul. 12, 2026. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €13.06 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Myriad Genetics ranks better than 95.79% on this metric.

Myriad Genetics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Myriad Genetics has Myriad Genetics has some exposure due to international sales and supply chains. However, its strong market position and pricing power provide resilience. Historical tariff impacts have been manageable.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Myriad Genetics might have Highly Resilient.

Myriad Genetics  (STU:MYD) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Myriad Genetics Tariff Resilience Score Related Terms

STU:MYD vs FLGT, CSTL, BDSX: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Tariff Resilience Score falls into.


STU:MYD
53GF Score
Myriad Genetics Inc STU:MYD
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Myriad Genetics (STU:MYD) has a Tariff Resilience Score of 7 as of Jul. 12, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Myriad Genetics ranks #9 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 4.2%.
Is Myriad Genetics' Tariff Resilience Score too high?
Myriad Genetics' current Tariff Resilience Score is 7. Based on the distribution chart, Myriad Genetics ranks #9 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Tariff Resilience Score compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #9 out of 214 companies for Tariff Resilience Score. This places Myriad Genetics in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Myriad Genetics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.06, compared to a current price of €5.09 — trading 61% below its estimated fair value. The current Tariff Resilience Score is 7. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Tariff Resilience Score is 7 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.09 is trading 61% below its estimated GF Value™ of €13.06. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Tariff Resilience Score: 7
  • GF Value™: €13.06 vs. price of €5.09 (61% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score

Get the complete analysis for STU:MYD

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09
Price
€13.06
GF Value